{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T09:05:42Z","timestamp":1772183142061,"version":"3.50.1"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jcpo.2025.100568","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T20:00:43Z","timestamp":1741464043000},"page":"100568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Adding adjuvant drugs from distinct breast cancer trials"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6936-5783","authenticated-orcid":false,"given":"Timoth\u00e9e","family":"Olivier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcpo.2025.100568_bib1","doi-asserted-by":"crossref","unstructured":"Schmid P., Cortes J., Dent R., et al. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. New England Journal of Medicine. 0(0). doi:10.1056\/NEJMoa2409932.","DOI":"10.1056\/NEJMoa2409932"},{"issue":"9","key":"10.1016\/j.jcpo.2025.100568_bib2","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1055\/a-2121-2495","article-title":"Treatment of early breast cancer: The 18th St. Gallen International breast cancer consensus conference against the background of current german treatment recommendations","volume":"83","author":"Untch","year":"2023","journal-title":"Geburtshilfe Frau"},{"key":"10.1016\/j.jcpo.2025.100568_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high risk, early breast cancer","author":"Geyer","year":"2022","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.jcpo.2025.100568_bib4","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1200\/OP.21.00770","article-title":"Q and A: a new standard of care for germline BRCA1 and\/or BRCA2 mutation carriers with early-stage breast cancer","volume":"18","author":"Desai","year":"2022","journal-title":"JCO Oncol. Pract."},{"issue":"9","key":"10.1016\/j.jcpo.2025.100568_bib5","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol."},{"issue":"22","key":"10.1016\/j.jcpo.2025.100568_bib6","article-title":"Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 Trial","volume":"41","author":"Es","year":"2023","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.jcpo.2025.100568_bib7","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcpo.2025.100568_bib8","author":"Rastogi","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.jcpo.2025.100568_bib9","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538325000128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538325000128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T08:22:17Z","timestamp":1772180537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538325000128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":9,"alternative-id":["S2213538325000128"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2025.100568","relation":{},"ISSN":["2213-5383"],"issn-type":[{"value":"2213-5383","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adding adjuvant drugs from distinct breast cancer trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2025.100568","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100568"}}